Essential points to remember are that GLP-1 and GIP analogues may be beneficial for people with ASCVD and/or obesity, alongside T2DM as this drug class has shown benefit in improving cardiovascular outcomes and reducing weight, both of which we know are intrinsically linked to T2DM
mTOR can be involved in various parts of tumor growth and development, such as proliferation, metastasis, survival, and angiogenesis
Clinical trials demonstrate a clear difference in how these two drug classes affect body weight
Surgery offers greater weight loss and health benefits, but is invasive
Effect of GIP and GLP-1 antagonists on insulin release in the rat
Moreover, the levels of vascular VEGF, angiopoietin, and platelet-derived growth factor (PDGF)-B&D were restored